Acadia Pharma (ACAD) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of $0.31, $0.11 better than the analyst estimate of $0.20. Revenue for the quarter came in at $342 million versus the consensus estimate of $332.42 million.
GUIDANCE:
Acadia Pharma sees FY2026 revenue of $1.27-1.3 billion, versus the consensus of $1.27 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Ingevity (NGVT) Tops Q3 EPS by 7c, Beats on Revenue; Offers FY26 EPS Guidance
- Seaport Entertainment Group Inc. (SEG) Tops Q3 EPS by 25c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
